<div id="readability-page-1"><div><p>Hybio Pharmaceutical Co., Ltd. announced private placement of shares for gross proceeds not more than CNY 968,000,000 on September 26, 2025. The shares are issued not more than 30% of total share capital and issue price is not less than 80% of the average price in the 20 trading days before the pricing reference date. The transaction includes participation from not more than 35 investors.</p><p>The transaction has been approved in the 7th Meeting of the Company?s 6th Directorate, and is subject to the approvals of the Company?s Shareholders, the Shenzhen Stock Exchange, and the China Securities Regulatory Commission. The shares cannot be transferred within 6 months from the issuance closing date.</p></div></div>

翰宇药业

<p>翰宇药业有限公司宣布进行私募配股，预计筹集资金最高可达 9.68 亿元人民币。此次发行将不超过总股本的 30%，最低发行价格为过去 20 个交易日平均价格的 80%。该交易已获得公司第六届董事会的批准，但仍需获得股东、深圳证券交易所和中国证券监督管理委员会的进一步批准。发行后，股份将在 6 个月内不可转让</p>

翰宇药业宣布预计将获得人民币 9.68 亿元的资金